
Kips Biopharma Files Patent for Revolutionary Oral Peptide Drug Delivery Platform 'Oraloid' – A Game-Changer for Obesity Treatment
Korean biotech company Kips Biopharma has filed a domestic patent for its groundbreaking oral peptide drug delivery platform 'Oraloid', showing 40x higher bioavailability than existing oral GLP-1 drugs in primate studies.